In this report for instance therapies directed against hepatic TTR synthesis for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) such as the AsO inotersen [92], the Lp(a) lowering siRNA SLN360 [93] and RNA-based therapies for the treatment of heart failure of ischemic origin, CDR132L, were not discussed. Here, TTR is linked to amyloidosis.